Literature DB >> 18832521

Early preservation of effector functions followed by eventual T cell memory depletion: a model for the delayed onset of the effect of thiopurines.

S Ben-Horin1, I Goldstein, E Fudim, O Picard, Z Yerushalmi, I Barshack, I Bank, Y Goldschmid, S Bar Meir, L Mayer, Y Chowers.   

Abstract

OBJECTIVE: The onset of the effect of thiopurines is delayed for several months. The aim of this study was to investigate immune mechanisms for this delay.
METHODS: The effects of thiopurines on human peripheral blood T cells and on lamina propria lymphocytes were investigated for apoptosis induction by Annexin V/propidium iodide (PI) and for cytokine secretion by intracellular staining and ELISA assays. To investigate the mechanism of the effect of thiopurines in vivo, Balb/C mice were co-immunised with HEL/OVA (hen egg lysozyme/ovalbumin) antigens, and then repeatedly challenged by HEL only, while being treated by mercaptopurine or vehicle alone for either 4 or 20 weeks. The memory response of CD4+ splenocytes towards HEL/OVA was then determined by CFSE (carboxyfluorescein succinimidyl ester) dilution.
RESULTS: Thiopurines arrested the proliferation of stimulated T cells but did not enhance the apoptosis of either resting T cells or activated T cells until day 5 poststimulation. Despite the proliferation arrest, stimulated T cells successfully differentiated into effector cells, as evidenced by their capacity for proinflammatory cytokine secretion, potent adhesion and cytotoxicity. Prolonged mercaptopurine treatment of mice for 20 weeks selectively reduced the CD4+ memory response to a repeatedly encountered HEL antigen, but did not affect the T cell memory pool to the previously presented OVA antigen. A shorter, 4 weeks, treatment with mercaptopurine did not inhibit the memory response to either antigen.
CONCLUSIONS: T cells arrested from cycling by thiopurines can still differentiate into potent effector cells capable of propagating the inflammatory process. Thiopurine treatment results in depletion of antigen-specific memory T cells, but this effect is dependent upon repeated encounters with the antigen over a prolonged time course.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18832521     DOI: 10.1136/gut.2008.157339

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  16 in total

1.  Thiopurines in IBD: What Is Their Mechanism of Action?

Authors:  Markus Neurath
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-07

2.  Increased lymphocyte apoptosis in mouse models of colitis upon ABT-737 treatment is dependent upon BIM expression.

Authors:  C Lutz; M Mozaffari; V Tosevski; M Caj; P Cippà; B L McRae; C L Graff; G Rogler; M Fried; M Hausmann
Journal:  Clin Exp Immunol       Date:  2015-05-19       Impact factor: 4.330

3.  Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.

Authors:  E Israeli; E Goldin; S Fishman; F Konikoff; A Lavy; Y Chowers; E Melzer; A Lahat; M Mahamid; H Shirin; E Nussinson; O Segol; A Ben Ya'acov; Y Shabbat; Y Ilan
Journal:  Clin Exp Immunol       Date:  2015-08       Impact factor: 4.330

Review 4.  Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease.

Authors:  Douglas L Nguyen; Sarah Flores; Kareem Sassi; Matthew L Bechtold; Emily T Nguyen; Nimisha K Parekh
Journal:  Ther Adv Chronic Dis       Date:  2015-05       Impact factor: 5.091

Review 5.  Update on the Use of Thiopurines and Methotrexate in Inflammatory Bowel Disease.

Authors:  Christopher M Johnson; Themistocles Dassopoulos
Journal:  Curr Gastroenterol Rep       Date:  2018-09-28

Review 6.  Use of thiopurines in inflammatory bowel disease: Safety issues.

Authors:  Anastasia Konidari; Wael El Matary
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-05-06

Review 7.  Pharmacological targeting of allergen-specific T lymphocytes.

Authors:  Peter A Tauber; Winfried F Pickl
Journal:  Immunol Lett       Date:  2017-03-18       Impact factor: 3.685

8.  Azathioprine therapy selectively ablates human Vδ2⁺ T cells in Crohn's disease.

Authors:  Neil E McCarthy; Charlotte R Hedin; Theodore J Sanders; Protima Amon; Inva Hoti; Ibrahim Ayada; Vidya Baji; Edward M Giles; Martha Wildemann; Zora Bashir; Kevin Whelan; Ian Sanderson; James O Lindsay; Andrew J Stagg
Journal:  J Clin Invest       Date:  2015-07-13       Impact factor: 14.808

9.  Normal response to vaccines in inflammatory bowel disease patients treated with thiopurines.

Authors:  Iris Dotan; Lael Werner; Sharon Vigodman; Shradha Agarwal; Jorge Pfeffer; Noya Horowitz; Lisa Malter; Maria Abreu; Thomas Ullman; Hanan Guzner-Gur; Zamir Halpern; Lloyd Mayer
Journal:  Inflamm Bowel Dis       Date:  2011-03-15       Impact factor: 5.325

Review 10.  Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease.

Authors:  Giovanni-C Actis; Rinaldo Pellicano; Mario Rizzetto; Muhammad Ayoubi; Nicola Leone; Gianfranco Tappero; Paola Pazienza; Floriano Rosina
Journal:  World J Gastroenterol       Date:  2009-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.